BIOPHARMA
By
Did Metabolic Therapy Approvals in 2025 Reset the Standard of Care—and Ignite a New Growth Cycle in 2026?
Global – December 2025 — The metabolic therapeutic area emerged as one of the most transformative forces in…
Did Renal Therapy Approvals in 2025 Redefine Kidney Disease Management—and Set the Stage for Breakthroughs in 2026?
Global – December 2025 — The renal therapeutic area emerged as a renewed focus of innovation in 2025,…
Did Cardiovascular Approvals in 2025 Signal a New Era in Heart Disease Management—and Set the Pace for 2026 Innovation?
Global – December 2025 — The cardiovascular (CV) therapeutic area re-emerged as a strategic growth engine in 2025,…
Did Infectious Disease Approvals in 2025 Redefine Global Preparedness—and Set the Course for Innovation in 2026?
Global – December 2025 — The infectious diseases (ID) landscape underwent a structural recalibration in 2025, shaped by…
Will Eli Lilly’s 2025 Earnings Prove That AI Is the Hidden Engine Behind Its Next Phase of Scale?
Late January 2026 | Full-Year 2025 Earnings Preview | AI-Driven Biopharma Leadership Eli Lilly is set to report…
Will Sanofi’s 2025 Earnings Cement Dupixent’s Leadership—and Its Next Growth Wave in Atopic Dermatitis?
Late January 2026 | Full-Year 2025 Earnings Preview | Immunology & Dermatology Focus Sanofi is set to report…
